---
layout: default
title: Loxoprofen
parent: 僅模型預測 (L5)
nav_order: 390
evidence_level: L5
indication_count: 2
---

# Loxoprofen
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Loxoprofen: From NSAID Pain/Inflammation Therapy to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome

## One-Sentence Summary

Loxoprofen is a non-selective COX-1/COX-2 inhibitor NSAID; a formally approved indication text is not available because the drug is currently **not marketed in Saudi Arabia**. The TxGNN model's top prediction is **colobomatous microphthalmia-rhizomelic dysplasia syndrome**, a rare developmental/chromosomal syndrome, but this is supported by **zero clinical trials and zero publications**, and the evidence pack itself flags the prediction as a likely knowledge-graph artifact rather than a biologically plausible signal.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not formally documented (drug not marketed in Saudi Arabia); drug class is NSAID (pain/inflammation) |
| Predicted New Indication | Colobomatous microphthalmia-rhizomelic dysplasia syndrome |
| TxGNN Prediction Score | 99.80% (rank 4030) |
| Evidence Level | L5 |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the evidence pack (marked as Data Gap). Based on known drug classification, Loxoprofen is a non-selective COX-1/COX-2 inhibitor NSAID, and its pharmacological action is suppression of prostaglandin synthesis to relieve pain and inflammation.

The predicted new indication, colobomatous microphthalmia-rhizomelic dysplasia syndrome, is a rare developmental/chromosomal syndrome (coloboma-associated small eye malformation combined with proximal limb dysplasia) caused by embryonic gene regulatory abnormalities. There is **no known pathogenic mechanism linked to the prostaglandin pathway**.

The evidence pack's own repurposing rationale is explicit on this point: the high TxGNN score (0.998) most likely reflects sparse node connectivity and embedding-similarity distortion for this rare-disease node in the knowledge graph, rather than genuine biological plausibility. The same caveat applies to the rank-2 candidate, brachydactyly-syndactyly syndrome (score 99.75%, also a congenital skeletal disorder tied to developmental gene pathways such as HOX, with no COX-pathway link and no supporting trials or literature). Both candidates carry the same L5 evidence level and Hold recommendation.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Saudi Arabia Market Information

No authorizations on record — Loxoprofen currently has 0 registered licenses and is not marketed in Saudi Arabia.

## Safety Considerations

Please refer to the package insert for safety information. Note: retrieval of the TFDA/SFDA package insert (warnings and contraindications) is currently a **blocking data gap**, which prevents this candidate from entering the S1 safety pre-screening stage.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction sits at evidence level L5 (model prediction only) with no clinical trials or literature support, and the evidence pack itself assesses the mechanistic link as implausible (likely a sparse-node artifact in the knowledge graph). Combined with the blocking data gap on TFDA/SFDA package insert safety data and the drug's current non-marketed status in Saudi Arabia, there is no basis to advance past S0.

**To proceed, the following is needed:**
- TFDA/SFDA package insert (warnings, contraindications) — required to clear the S1 safety pre-screen (currently blocking)
- Confirmed mechanism of action (MOA) data from DrugBank or another authoritative source
- Independent mechanistic or preclinical evidence connecting COX inhibition to either candidate syndrome, given the current rationale assesses the link as absent
- Re-evaluation if future clinical trials, case reports, or literature emerge for either indication
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

